Compare Generiks, Inc.
Ticker: COGE 300 Oser Avenue
Exchange: NASDAQ-Small Cap Market Hauppauge, New York 11788
Industry: Manufacturing (800) 342-6555

Type of Shares:Common Shares Filing Date:12/21/95
U.S. Shares:690,000 Offer Date:3/6/96
Non-U.S. Shares:0 Filing Price:$5.00
Primary Shares:690,000 Offer Price:$5.00
Secondary Shares:0 Gross Spread:$0.50
Offering Amount: $3,450,000 Selling:$0.25
Expenses:$600,500 Reallowance:
Shares Out After:3,690,000
Spin out parent firm: Walpac, Inc.

ManagerTierPhone
VTR Capital, Inc.Lead Manager (303) 756-0909

Auditor: Holtz Rubenstein & Co.
Audited
Income
Latest
Unaudited
Income
Prior
Unaudited
Income
Balance
Sheet
10/31/95 10/31/95
Revenue:$0.00Assets:$2.05
Net Income:$0.20Liabilities:$0.81
EPS:-$0.07Equity:$1.24

Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year,
unaudited figures are partial year

Business Description
The company is engaged in the distribution, marketing and sale of dietary supplements and over the counter non-prescription pharmaceuticals. The company distributes its products under company owned trademarks through direct sales to major wholesalers, particularly those that service convenience stores, drug stores, discount department stores, wholesale clubs, petroleum marketers, hospital gift shops and airport gift shops supported by a sophisticated broker network. The company focuses its marketing efforts on a gravity fed display containing the Compare Generiks label products which are comparable to the thirteen top national brand non prescription products sold in the market today. A gravity fed display is designed to restock the shelf display automatically as each unit of product is removed. On October 31, 1995, the company acquired from PDK Labs, Inc. certain assets and rights relating to the Energex Plus product line, including all interest in the Energex Plus market, customer list, trade secrets, trademarks, and trade names, including the use of the tradename "energex Plus". In addition, concurrently the company also acquired from PDK all the assets and rights relating to the "Compare Generiks" product line.

Use of Proceeds
The proceeds from the proposed offering will be used for marketing and advertising; repayment of certain indebtedness, and working capital.

Last updated: 10/28/96

©1996 IPO Data Systems, Inc. - All rights reserved.